Lava Competitors

Delisted . USA . 
Stock . Lava Medtech Acquisition
Lava Medtech Acquisition competes with Analog Devices, Molecular Partners, FARO Technologies, Paysafe, and Highway Holdings; as well as few others. The company classifies itself under Financial Services sector and is part of Shell Companies industry. Analyzing Lava Medtech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Lava Medtech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Lava Medtech competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lava Medtech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Lava Medtech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lava Medtech and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Lava and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lava Medtech Acquisition does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PH
+ 0.83
PSFE
CHX
+ 0.64
FARO
PH
+ 0.5
CHX
PH
+ 0.37
FARO
CHX
+ 0.37
PSFE
HIHO
+ 0.34
MOLN
  
High negative correlations   
HIHO
- 0.54
FARO
CHX
- 0.39
HIHO
PH
- 0.17
HIHO
HIHO
- 0.17
ADI
HIHO
- 0.15
PSFE
FARO
- 0.11
MOLN

Risk-Adjusted Indicators

There is a big difference between Lava Stock performing well and Lava Medtech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lava Medtech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Lava Medtech Competitive Analysis

The better you understand Lava Medtech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lava Medtech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lava Medtech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ADI UNMK MOLN FARO PSFE HIHO CHX PH
 2.43 
 208.75 
Analog
 0.00 
 0.08 
Tritent
 1.37 
 4.33 
Molecular
 4.44 
 29.43 
FARO
 3.88 
 15.81 
Paysafe
 3.68 
 1.83 
Highway
 3.09 
 29.37 
ChampionX
 2.74 
 607.88 
Parker
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Slightly risky
Not too volatile
Not too volatile
Moderately volatile
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Very Weak
Insignificant
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very Low
Above Average
Low
Low
Very Small
Low
Very Small
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Fairly Valued
Under Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Not Available
Strong Buy
Strong Buy
Hold
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Buy
Strong Sell
Hold
Buy
Hold
Hold
Strong Hold
Strong Hold
Current Ratio
2.02 X
N/A
14.37 X
2.57 X
1.06 X
3.03 X
1.85 X
2.06 X
Net Asset
48.23 B
1.71 M
158.53 M
483 M
4.81 B
11.32 M
3.47 B
29.3 B
Profit Margin
0.17 %
N/A
N/A
(0.03) %
0.01 %
(0.07) %
0.09 %
0.16 %
EBITDA
2.03 B
N/A
(51.65 M)
3.33 M
429.58 M
(11 K)
744.57 M
5.03 B
Operating Margin
0.23 %
N/A
(12.32) %
0.08 %
0.07 %
0.05 %
0.16 %
0.21 %
Current Valuation
107.32 B
(600.26 K)
(10.07 M)
528.79 M
3.1 B
4.11 M
5.65 B
87.6 B
Price To Book
2.92 X
N/A
1.01 X
2.16 X
1.04 X
1.29 X
2.96 X
6.02 X
Retained Earnings
10.2 B
(2.9 M)
(246.29 M)
(18.86 M)
(2.24 B)
(5.01 M)
(239.05 M)
19.1 B
Current Asset
4.97 B
9 K
N/A
292.16 M
N/A
15.73 M
N/A
5.21 B
Five Year Return
1.88 %
N/A
N/A
N/A
N/A
8.82 %
N/A
1.61 %
Beta
1.07
-13.72
0.63
1.55
1.88
0.093
2.29
1.5
Number Of Employees
24 K
5
158
1.18 K
3.3 K
N/A
7.1 K
61.12 K
Shares Outstanding
495.98 M
3.39 M
36.87 M
18.98 M
59.89 M
4.4 M
190.8 M
128.76 M
Cash Flow From Operations
3.85 B
(214.62 K)
(59.25 M)
30.63 M
253.8 M
415 K
589.68 M
3.38 B
Annual Yield
0.02 %
N/A
N/A
N/A
N/A
0.10 %
0.01 %
0.01 %
Total Debt
7.58 B
N/A
2.44 M
88.8 M
2.41 B
1.39 M
695.79 M
10.56 B
Return On Equity
0.0443
N/A
-0.34
-0.035
0.0252
-0.0709
0.19
0.26
Z Score
N/A
-1.4
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0262
N/A
-0.21
0.0082
0.0171
-0.0196
0.0963
0.0878
Number Of Shares Shorted
7.03 M
N/A
42.6 K
915.7 K
1.22 M
28.06 K
9.63 M
1.14 M
Book Value Per Share
70.71 X
0.18 X
3.84 X
13.17 X
14.68 X
1.54 X
9.68 X
101.88 X
Current Liabilities
782.93 M
1.38 M
N/A
63.03 M
N/A
5.07 M
N/A
2.37 B
Total Asset
48.23 B
1.71 M
158.53 M
483 M
4.81 B
11.32 M
3.47 B
29.3 B
Debt To Equity
0.19 %
N/A
0.02 %
0.07 %
2.96 %
0.06 %
0.43 %
1.31 %
Short Ratio
1.83 X
N/A
26.80 X
4.01 X
3.02 X
0.20 X
2.84 X
1.54 X
Target Price
261.3
N/A
10.74
38.5
18.17
N/A
42.6
748.38
Last Dividend Paid
3.75
N/A
N/A
N/A
N/A
0.07
0.38
6.37
Shares Owned By Institutions
92.71 %
N/A
9.72 %
96.27 %
58.83 %
4.16 %
93.40 %
88.40 %
Market Capitalization
101.08 B
169.39 K
161.88 M
534.9 M
911.5 M
8.52 M
5.44 B
76.18 B
Price To Earning
49.43 X
N/A
1.85 X
46.93 X
N/A
13.78 X
81.16 X
24.97 X
Price To Earnings To Growth
0.88 X
N/A
N/A
(19.38) X
N/A
N/A
1.93 X
2.47 X
Price To Sales
10.82 X
N/A
32.57 X
1.56 X
0.53 X
1.14 X
1.50 X
3.83 X
Net Income
1.64 B
(214.62 K)
(54.04 M)
(9.07 M)
22.16 M
(978 K)
327.13 M
2.84 B
Earnings Per Share
3.12 X
N/A
(1.80) X
(0.47) X
0.36 X
(0.11) X
1.65 X
24.20 X
Shares Owned By Insiders
0.23 %
N/A
N/A
3.73 %
24.44 %
39.81 %
1.13 %
0.20 %
Revenue
9.43 B
N/A
4.97 M
342.43 M
1.7 B
6.32 M
3.63 B
19.93 B
Working Capital
2.5 B
(1.37 M)
143.5 M
135.31 M
231.06 M
5.81 M
778.02 M
(514.68 M)
Cash And Equivalents
1.47 B
1.7 M
267.13 M
101.97 M
220.19 M
6.01 M
187.47 M
475.18 M
Cash Per Share
2.89 X
0.24 X
8.22 X
5.58 X
0.30 X
1.48 X
0.94 X
4.39 X
Gross Profit
5.34 B
N/A
(42.53 M)
187.15 M
989.07 M
3.14 M
1.19 B
7.22 B
Day Typical Price
208.28
0.082
4.34
29.14
15.79
1.83
29.21
603.55
Accumulation Distribution
43815.75
N/A
2.67
7765.64
17024.51
20.37
172415.0
22537.59
Daily Balance Of Power
1.367403
0.0
(3.00)
1.262626
0.8676
(2.33)
0.9565
1.099593
Period Momentum Indicator
4.95
N/A
(0.06)
1.25
0.59
(0.07)
0.88
16.23
Rate Of Daily Change
1.02
1.0
0.99
1.04
1.04
0.96
1.03
1.03
Day Median Price
208.04
0.082
4.34
28.99
15.78
1.84
29.13
601.38
Price Action Indicator
3.19
N/A
(0.04)
1.06
0.33
(0.04)
0.68
14.62
Coefficient Of Variation
(5,206)
N/A
(914.03)
2339.89
(1,480)
13755.16
(5,296)
(739.58)
Mean Deviation
1.56
N/A
2.32
2.71
2.58
1.01
1.52
1.22
Jensen Alpha
0.1284
N/A
(0.10)
0.3285
(0.05)
3.0E-4
0.0956
(0.06)
Total Risk Alpha
0.315
N/A
0.1888
0.8433
0.439
0.2493
0.297
0.0456
Sortino Ratio
N/A
N/A
N/A
0.1083
N/A
0.0773
N/A
N/A
Downside Variance
N/A
N/A
N/A
7.92
N/A
3.42
N/A
N/A
Standard Deviation
2.18
N/A
3.36
4.04
4.45
1.47
2.05
1.67
Kurtosis
5.27
N/A
1.3
7.8
8.8
1.67
1.67
2.18
Potential Upside
2.52
N/A
7.09
4.78
3.72
2.65
3.01
2.06
Treynor Ratio
(0.04)
N/A
(0.20)
0.1395
(0.17)
(0.24)
(0.05)
(0.20)
Maximum Drawdown
13.98
N/A
17.19
22.69
35.03
7.72
12.12
10.15
Variance
4.74
N/A
11.32
16.31
19.78
2.18
4.21
2.79
Market Risk Adjusted Performance
(0.03)
N/A
(0.19)
0.1495
(0.16)
(0.23)
(0.04)
(0.19)
Risk Adjusted Performance
(0.01)
N/A
(0.08)
0.044
(0.05)
0.0104
(0.01)
(0.11)
Skewness
0.9451
N/A
0.3187
2.27
(1.09)
(0.07)
0.2598
0.0244
Semi Deviation
N/A
N/A
N/A
2.7
N/A
1.37
N/A
N/A
Information Ratio
0.0415
N/A
(0.07)
0.0755
(0.04)
0.0969
0.0456
(0.06)
Value At Risk
(3.66)
N/A
(5.85)
(4.13)
(5.69)
(2.16)
(3.09)
(3.50)
Expected Short fall
N/A
N/A
N/A
(3.15)
N/A
(1.25)
N/A
N/A
Downside Deviation
N/A
N/A
N/A
2.81
N/A
1.85
N/A
N/A
Semi Variance
N/A
N/A
N/A
7.3
N/A
1.88
N/A
N/A

Lava Medtech Competition Performance Charts

Five steps to successful analysis of Lava Medtech Competition

Lava Medtech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lava Medtech Acquisition in relation to its competition. Lava Medtech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Lava Medtech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lava Medtech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lava Medtech Acquisition, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Lava Medtech position

In addition to having Lava Medtech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Marketing Thematic Idea Now

Marketing
Marketing Theme
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Lava Stock

If you are still planning to invest in Lava Medtech Acquisition check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lava Medtech's history and understand the potential risks before investing.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY